دورية أكاديمية
أعرض في EDS

New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes.

التفاصيل البيبلوغرافية
العنوان: New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes.
المؤلفون: Vergote, Ignace, Bours, Vincent, Blaumeiser, Bettina, Baurain, Jean-François
المساهمون: UCL - SSS/IREC/MIRO - Pôle d'imagerie moléculaire, radiothérapie et oncologie, UCL - (SLuc) Unité d'oncologie médicale
المصدر: Facts, views & vision in ObGyn, Vol. 8, no.3, p. 161-167 (2016)
بيانات النشر: Flemish Society of Obstetrics & Gynaecology
سنة النشر: 2016
المجموعة: DIAL@UCL (Université catholique de Louvain)
مصطلحات موضوعية: BRCA 1, BRCA 2, Cancer, Maintenance therapy, Platinum-sensitive recurrent ovarian cancer
الوصف: Ovarian cancer (OC) is the seventh most common cancer in women. Although women diagnosed with OC are usually treated frontline with platinum-based chemotherapy, most of them relapse once treatment is halted. Therefore, maintenance therapies have been developed to secure the response and delay further chemotherapy. There are two established maintenance therapies for women affected by platinum-sensitive recurrent OC: bevacizumab, a humanized monoclonal antibody targeting vascular endothelial growth factor, and olaparib, an inhibitor of poly (adenosine diphosphate [ADP]-ribose) polymerase (PARPi). Loss-of-function mutations in genes in the homologous recombination pathway, especially BRCA1 and BRCA2, predict higher rates of platinum sensitivity, better overall survival (OS), and better response to PARPi in women with OC. Among patients with platinum-sensitive recurrent OC, a BRCA mutation is the first genetically defined predictive marker for targeted therapy, since these patients are most likely to benefit from treatment with a PARPi, such as olaparib. In patients with platinum-sensitive recurrent OC without a BRCA mutation, bevacizumab currently seems to be the best maintenance option. Women with OC are progressively more routinely screened for germline BRCA mutations, and the implication of somatic BRCA mutations is increasingly being recognized in OC. Therefore, the recommendations should be updated to reflect the importance of both types of mutations. Together, these data highlight the fact that treatment of recurrent OC can be optimized using genomic contributions to individualize therapy and to improve treatment response.
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 2032-0418
العلاقة: boreal:182696; http://hdl.handle.net/2078.1/182696Test; info:pmid/28003870; urn:ISSN:2032-0418
الإتاحة: http://hdl.handle.net/2078.1/182696Test
حقوق: info:eu-repo/semantics/openAccess
رقم الانضمام: edsbas.EBB17729
قاعدة البيانات: BASE
الوصف
تدمد:20320418